We are developing a ground-breaking new therapy with the potential to slow or reverse the course of Alzheimer’s Disease (AD). Current approved AD treatments only help people with their symptoms and do not address the fundamental drivers of the disease, such as inflammation. The high failure rate from many agents targeting a single disease driver, typically via the amyloid or tau pathways, has not translated into real benefits for patients, even though they looked promising in the laboratory. AD has complex biology, meaning that many processes within the brain need to be corrected in people with AD. We believe that a successful drug for AD will need to address more than one of these processes at the same time. We recognise there is a strong unmet need for new drugs to improve the lives of people with AD and we strongly believe the way to achieve this is with a new mechanism that can correct underlying inflammatory processes that drive the disease. 

The biological target in our project offers the advantage of simultaneously modulating more than one pathway in AD, and, excitingly, this can be done through a single molecular target meaning only one drug is required. By inhibiting a single target, we have shown that our compound strongly reduces inflammation in the brain and shows beneficial effects on both the tau and amyloid pathways. Brain inflammation is critical to address in AD patients, because it is known to be one of the earliest signals and drivers of disease. Our candidate drug will be first-in-class because no-one has clinically evaluated modulators of this target for treating neurodegenerative disease. By tackling the disease early and through key disease drivers, our drug promises to bring meaningful improvements in health outcomes and quality of life for people living with AD.